Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Issues
2018
August 2018, Vol 9, No 2
August 2018, Vol 9, No 2 | Payers’ Perspectives In Oncology: ASCO
Immunotherapy Combinations “Raising the Bar”
By
Phoebe Starr
Immunotherapy
,
Personalized Medicine
August 2018, Vol 9, No 2 | Payers’ Perspectives In Oncology: ASCO
Read Article
Less Is More: Six Months of Trastuzumab Equivalent to 12 months in HER2-Positive Breast Cancer
By
Phoebe Starr
Breast Cancer
August 2018, Vol 9, No 2 | Payers’ Perspectives In Oncology: ASCO
“We are confident that this will mark the first steps toward a reduction of the duration of trastuzumab in many women with HER2-positive breast cancer,” says Helena M. Earl, MBBS, PhD, FRCP.
Read Article
Discussing Costs with Your Patient Can Reduce Financial Toxicity
By
Chase Doyle
Economics & Value
,
Financial Toxicity
,
Value-Based Care
August 2018, Vol 9, No 2 | Payers’ Perspectives In Oncology: ASCO
“Treating financial toxicity at the patient level is similar to treating a symptom like fatigue. You can try to prevent it, but to some degree, patients are going to experience it, and when they do, you need a plan,” says Yousuf Zafar, MD, MHS.
Read Article
Chemotherapy Can Be Spared in Many Patients with Early Breast Cancer: Devil Is in the Details
By
Phoebe Starr
Breast Cancer
,
Chemotherapy
,
Personalized Medicine
August 2018, Vol 9, No 2 | Payers’ Perspectives In Oncology: ASCO
Read Article
Precision Medicine and Immunotherapy Highlighted at ASCO 2018
By
Wayne Kuznar
August 2018, Vol 9, No 2 | Payers’ Perspectives In Oncology: ASCO
Interest in personalizing medicine in oncology is growing, so the American Society of Clinical Oncology (ASCO) titled its theme for the 2018 presidential address at the annual meeting, "Delivering Discoveries: Expanding the Reach of Precision Medicine."
Read Article
First-in-Class Antibody-Drug Conjugate Effective in HER2-Negative Metastatic Breast Cancer
By
Chase Doyle
Breast Cancer
August 2018, Vol 9, No 2 | Payers’ Perspectives In Oncology: ASCO
Read Article
Pembrolizumab as a First-Line Standard-of-Care Option in Advanced Non–Small-Cell Lung Cancer
By
Wayne Kuznar
Lung Cancer
,
Solid Tumors
,
Personalized Medicine
August 2018, Vol 9, No 2 | Payers’ Perspectives In Oncology: ASCO
Read Article
With Access to Care, Black Men in the United States Have Same Prostate Cancer Outcomes as White Men
By
Phoebe Starr
Prostate Cancer
,
Solid Tumors
,
Personalized Medicine
August 2018, Vol 9, No 2 | Payers’ Perspectives In Oncology: ASCO
Read Article
Page 3 of 3
1
2
3
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
Wayne Kuznar
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma